Management

Management

PxRadia mAb Technologies is guided by an experienced team headed by Dr. Alton C. Morgan, a successful serial entrepreneur and renowned monoclonal antibody technical expert.

Alton C. Morgan, Ph.D., President & CEO


An internationally recognized scientist and entrepreneur with over 100 publications and inventions protected in 56 patents or patent applications. Dr. Morgan is a recognized expert in monoclonal antibody development and commercialization. Dr. Morgan was the founder of four biotechnology companies, PxRadia, Inc., Receptagen, Ltd., Phoenix Biomedical, Inc., and NeoRx Corp. He has a strong track record in managing technology from inception through development, intellectual property protection, and FDA approval. His unique experience in new technology assessment and in obtaining venture and corporate support for biotechnology development makes him ideally suited for the Company’s CEO position having a long successful history in the development and implementation to accelerate corporate growth.

Gail Thurston, V.P. Corporate Development


Ms. Thurston was most recently responsible for business and Corporate Development at Apthera Inc., raising nearly $7M in 3 rounds; the Company was subsequently merged into a NASDAQ traded Company (Galena Biopharma, GALE). She was also responsible for investor relations, public relations and business development for PxRadia Biotechnology Inc., a publicly-traded (TSX, Canada), monoclonal antibody development company, of which she was a co-founder. Gail was formerly the Director of Corporate Communications for Receptagen Corp., a former TSE listed company that was involved in cancer drug development. Prior to these positions, she worked in investor relations and the financing areas of several early-stage public companies. Gail has recently raised over $20M in seed capital for her last three companies. Gail will help raise the seed capital and follow-on equity rounds for PxRadia.

Scientific Advisory Board

Dr. Heinz Kohler, M.D., Ph.D.


Dr. Heinz Kohler is the President and Chief Scientific Officer at ImmPheron Inc., Lexington, KY and inventor of the HD technology. Dr. Heinz Kohler, holds both a MD. and Ph.D. degree and has long-standing experience in the development of antibodies, documented in over 200 peer-reviewed publications. He has been a former Professor at the University of Chicago, the University of SUNY at Buffalo and the University of California San Diego, and Director of Molecular Immunology at the Roswell Park Cancer Center. He was instrumental in the early start-up phase of IDEC Pharmaceuticals, one of the most successful biotech/ pharmaceutical companies to date as Director of Research.